Patents Assigned to Emory University
  • Patent number: 7282556
    Abstract: Polypeptides that can modulate SIRP?-CD47 functions and methods of use of the polypeptides are presented. In addition, polynucleotides that encode the polypeptides referred to above are presented. Further, pharmaceutical compositions to treat conditions are presented.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: October 16, 2007
    Assignee: Emory University
    Inventor: Charles A. Parkos
  • Publication number: 20070197462
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Application
    Filed: December 4, 2006
    Publication date: August 23, 2007
    Applicants: Pharmasset, Inc., Beth Israel Deaconess Medical Center, Emory University
    Inventors: Raymond Schinazi, Junxing Shi, Erik Gustafson, Joyce Fingeroth
  • Patent number: 7255991
    Abstract: Template-directed processes for synthesizing polymers are presented in which a sequence-specific polymer is generated from a corresponding sequence-specific template. The generated polymer has a chain length that corresponds to the chain length of the template.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: August 14, 2007
    Assignee: Emory University
    Inventors: David Lynn, Xiaoyu Li
  • Publication number: 20070178523
    Abstract: The present invention relates to novel druggable regions discovered in histone H3 lysine methyltransferase DIM-5, which is a SET domain protein. The present invention further relates to methods of using the druggable regions to screen potential candidate therapeutics for diseases in which the activity of SET domain proteins are implicated, for example, anti-cancer/anti-proliferative agents or anti-fungal agents.
    Type: Application
    Filed: August 6, 2003
    Publication date: August 2, 2007
    Applicant: Emory University
    Inventors: Xiaodong Cheng, Xing Zhang
  • Patent number: 7247709
    Abstract: The present invention relates to new genes encoding for the production of novel proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.
    Type: Grant
    Filed: March 15, 2006
    Date of Patent: July 24, 2007
    Assignee: Emory University
    Inventors: J. David Lambeth, Kathy K. Griendling, Bernard P. Lassegue, Rebecca S. Arnold, Guangjie Cheng
  • Patent number: 7244830
    Abstract: A glycopolymer composition is provided comprising glycopolymer molecules having a polymer backbone; a first pendent unit comprising a linking group connected to said polymer backbone and a saccharide moiety connected to said linking group, optionally a second pendent unit; a phenyl ring at a first end of the polymer backbone; and a cyanoxyl group at the second end of the polymer backbone, useful as intermediates for making bioactive glycopolymers which bind to bioactive molecules, viruses, cells and substrates for protein separation, cell culture, ad drug delivery systems, as well as in targeting for treatment of wound healing and other pathological conditions.
    Type: Grant
    Filed: January 14, 2002
    Date of Patent: July 17, 2007
    Assignee: Emory University
    Inventors: Elliot L. Chaikof, Daniel Grande, Subramanian Baskaran
  • Patent number: 7244590
    Abstract: The present invention relates to nucleotides encoding for the production of novel regulatory proteins for Nox enzymes involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these nucleotides, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these nucleotides and proteins, and methods to determine the activity of drugs to affect the biological activity of the regulatory proteins of the present invention.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: July 17, 2007
    Assignee: Emory University
    Inventors: J. David Lambeth, Guangjie Cheng
  • Patent number: 7226769
    Abstract: The present invention relates to new genes encoding for the production of novel proteins involved in generation of reactive oxygen intermediates and in peroxidative reactions that affect biological functions including cell division, thyroid hormone biosynthesis and tissue fibrosis. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: June 5, 2007
    Assignee: Emory University
    Inventors: J. David Lambeth, Bernard P. Lassegue, Kathy K. Griendling, Rebecca S. Arnold, Guangjie Cheng, Lisa Sharling, Guy Benian, William A. Edens
  • Patent number: 7223583
    Abstract: The present invention relates to novel antithrombotic variants of thrombin or fragments thereof that are capable of proteolytically activating protein C, but which are substantially free of fibrinogen cleavage activity. The present invention further relates to variant polypeptides that may be cleaved to yield active thrombin variants. The present invention also relates to methods of inhibiting thrombus formation in an animal or human subject by delivering an antithrombotic variant thrombin of the present invention to the blood of the subject. The present invention relates also to methods that use the novel variant thrombins for determining the level of protein C activation in a blood sample, or the thrombogenic potential of a patient.
    Type: Grant
    Filed: October 31, 2003
    Date of Patent: May 29, 2007
    Assignee: Emory University
    Inventors: Andras Gruber, Stephen R. Hanson, Enrico De Cera
  • Patent number: 7211570
    Abstract: A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: May 1, 2007
    Assignees: Pharmasset, Inc., Emory University, Beth Israel Deaconess Medical Center
    Inventors: Raymond F. Schinazi, Junxing Shi, Joyce D. Fingeroth, Erik Gustafson
  • Publication number: 20070082879
    Abstract: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC).
    Type: Application
    Filed: June 19, 2006
    Publication date: April 12, 2007
    Applicant: Emory University
    Inventor: Mark Goodman
  • Patent number: 7202052
    Abstract: The present invention relates to new genes encoding for the production of novel nox enzyme proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: April 10, 2007
    Assignee: Emory University
    Inventors: J. David Lambeth, Guangjie Cheng
  • Patent number: 7202053
    Abstract: The present invention relates to new genes encoding for the production of novel nox enzyme proteins involved in generation of reactive oxygen intermediates that affect cell division. The present invention also provides vectors containing these genes, cells transfected with these vectors, antibodies raised against these novel proteins, kits for detection, localization and measurement of these genes and proteins, and methods to determine the activity of drugs to affect the activity of the proteins of the present invention.
    Type: Grant
    Filed: May 20, 2004
    Date of Patent: April 10, 2007
    Assignee: Emory University
    Inventors: J. David Lambeth, Guangjie Cheng
  • Publication number: 20070078117
    Abstract: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.
    Type: Application
    Filed: September 27, 2006
    Publication date: April 5, 2007
    Applicant: Emory University
    Inventors: Stuart Hoffman, Arthur Kellermann, Donald Stein, David Wright, Douglas Lowery-North
  • Patent number: 7189357
    Abstract: An immunological or immunohematological assay system is disclosed that includes a filter vessel capable of containing an assay sample, an incubator, a sample separation system, an image acquisition system, and a robotic pipettor. The immunological assay system may also include a washer. Also disclosed is an immunological assay method that includes the steps of placing a immunological assay sample in a filter vessel, which includes a filter, adding testing reagents to the filter vessel, incubating the sample and reagent mixture in the filter vessel, separating the sample and reagent mixture in the filter vessel into components above and below the filter, and analyzing the filter vessel to determine the presence of interactions between the sample and reagents.
    Type: Grant
    Filed: January 31, 2001
    Date of Patent: March 13, 2007
    Assignee: Emory University
    Inventors: John D. Roback, Christopher D. Hillyer
  • Publication number: 20070027406
    Abstract: Cognitive assessment systems and methods that provide an integrated solution for evaluating the presence or absence of cognitive impairment. The present invention is used to test cognitive functions of an individual including information processing speed, working memory, work list learning and recall, along with variations of these tasks. Immersive and non-immersive systems and methods are disclosed. Testing and results feedback using the present invention may be completed in real time, typically in less than 15 minutes.
    Type: Application
    Filed: August 10, 2006
    Publication date: February 1, 2007
    Applicants: Georgia Tech Research Corporation, Emory University
    Inventors: Michelle LaPlaca, David Wright
  • Patent number: 7160999
    Abstract: A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (?)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: January 9, 2007
    Assignee: Emory University
    Inventors: Dennis C. Liotta, Raymond F. Schinazi, Woo-Baeg Choi
  • Publication number: 20060292073
    Abstract: The radiolabeled non-natural amino acid 1-amino-3-cyclobutane-1-carboxylic acid (ACBC) and its analogs are candidate tumor imaging agents useful for positron emission tomography and single photon emission computed tomography due to their selective affinity for tumor cells. The present invention provides methods for stereo-selective synthesis of syn-ACBC analogs. The disclosed synthetic strategy is reliable and efficient and can be used to synthesize a gram quantity of various syn-isomers of the ACBC analogs, particularly, syn-[18F]-1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC) and syn-[123I]-1-amino-3-iodocyclobutane-1-carboxylic (IACBC) acid analogs.
    Type: Application
    Filed: June 19, 2006
    Publication date: December 28, 2006
    Applicant: Emory University
    Inventors: Mark Goodman, Weiping Yu
  • Patent number: 7148027
    Abstract: A method of measuring the individual response to antidepressant drug therapy on the transport inhibition of monoamine neurotransmitters involves in vitro monitoring of radiolabeled monoamine neurotransmitter transport into cells transfected with transport proteins similar to those on neural cells of the individual being studied. The transport occurs in unbuffered serum of the individual who is undergoing or will later undergo pharmaceutical treatment for depression or other neuropsychiatric disorders. The use of buffers is avoided so that the sensitive balance of bound/free drug within the individuals serum is not disrupted prior to or during testing.
    Type: Grant
    Filed: February 25, 2003
    Date of Patent: December 12, 2006
    Assignee: Emory University
    Inventors: Michael J. Owens, Charles B. Nemeroff
  • Patent number: 7142910
    Abstract: Controlled cessation of heart beat during coronary bypass surgery and other cardiac surgeries on a beating heart improves surgical technique, and is achieved typically by electrical stimulation of the vagus nerve and administration of a combination of drugs.
    Type: Grant
    Filed: December 17, 2004
    Date of Patent: November 28, 2006
    Assignee: Emory University
    Inventor: John D. Puskas